Approval · Notice of Compliance 29123 · 2022
BOTOX: Notice of Compliance 29123
Issued October 3, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29123
- Date
- October 3, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
Medicinal ingredients
- ONABOTULINUMTOXINA 50 UNIT per VIAL
- ONABOTULINUMTOXINA 100 UNIT per VIAL
- ONABOTULINUMTOXINA 200 UNIT per VIAL